INS and diabetes mellitus: Clinical trials with rHuPH20 have been undertaken in the areas of rapid large volume hydration (10,11), rapid insulin and insulin analog delivery in subjects with diabetes (12–15), and delivery of large proteins such as immunoglobulins and monoclonal antibodies by SC rather than intravenous (IV) injections (9,16–21).